Investors of Ultragenyx Pharmaceutical Inc. (RARE) Must Act before April 6, 2026

Pharmaceutical Inc. (NASDAQ: RARE)
What: Securities fraud class action lawsuit filed
Class Period: August 3, 2023, through December 26, 2025
Deadline to seek lead plaintiff status: April 6, 2026
Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s drug, setrusumab
Investor action: Contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost to investors

A recent securities fraud class action lawsuit has been initiated against Ultragenyx Pharmaceutical Inc. (Ultragenyx) (NASDAQ: RARE) for investors who purchased or obtained Ultragenyx common stock between August 3, 2023, and December 26, 2025. The lawsuit, filed in the United States District Court for the Northern District of California under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 (N.D. Cal.), allows investors until April 6, 2026, to request lead plaintiff status.

Throughout the Class Period, it is alleged that Ultragenyx Pharmaceuticals Inc. misled investors by failing to disclose crucial information related to the company’s drug, setrusumab. The company is said to have painted an overly optimistic picture of the drug’s success in treating patients with various types of Osteogenesis Imperfecta. However, these assertions were supposedly based on flawed data that did not account for essential considerations such as the absence of a placebo control group in Phase II studies, which could have skewed effectiveness results.

Investors who suffered losses in connection with Ultragenyx Pharmaceutical Inc. between the stated period are encouraged to take action by April 6, 2026, to potentially be appointed as a lead plaintiff representative of the class. Seeking lead plaintiff status through Kessler Topaz Meltzer & Check, LLP or other appointed counsel is essential to participate in possible recovery. A lead plaintiff serves as the focal point for all class members in legal proceedings, representing their collective interests in the litigation and selecting counsel on their behalf.

Ultragenyx investors have the option to either participate in the legal process or remain as absent class members. The decision to become a lead plaintiff does not affect an investor’s right to share in any potential recovery. It is crucial for investors to engage with the legal process promptly to explore their options fully.

Kessler Topaz Meltzer & Check, LLP is a reputable U.S. law firm specializing in securities-fraud class actions and safeguarding global investor interests. With accolades for leading significant recoveries in securities litigation, the firm offers individual and institutional investors expert legal representation and advocacy. Investors affected by allegations against Ultragenyx Pharmaceutical Inc. can contact Kessler Topaz Meltzer & Check, LLP for further information on their legal rights and potential actions.